Regencell Bioscience Holdings Limited RGC NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • HK • USD

SharesGrow Score

53/100

2/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Regencell Bioscience Holdings Limited (RGC) has a negative trailing P/E of -3,929.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -0.03%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -3,929.2); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -0.03%).
Trailing Earnings Yield -0.03% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.

Overall SharesGrow Score: 50/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

53/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

✓

GROWTH

100/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — RGC

Valuation Multiples

P/E (TTM)-3,929.2

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio2,897.58

P/S Ratio0.00

EV/EBITDA-4,014.3

Per Share Data

EPS (TTM)$-0.01

Book Value / Share$0.01

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings Yield-0.03%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	Dividend Yield
2019	-73,720.6	0.00	-15,677.82	-
2020	-35,481.3	-324.96	-10,873.32	-
2021	-21,402.7	-330.77	-7,210.26	-
2022	-3,997.1	-9.17	1,738.56	-
2023	-5,053.4	244.52	2,466.21	-
2024	-6,896.9	256.48	3,609.98	-
2025	-2,350.9	136.35	1,733.67	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2019	$0.00	$0.00	$-390.99K	-
2020	$0.00	$0.00	$-812.37K	-
2021	$0.00	$0.00	$-1.35M	-
2022	$-0.01	$0.00	$-7.42M	-
2023	$-0.01	$0.00	$-5.87M	-
2024	$-0.01	$0.00	$-4.3M	-
2025	$-0.01	$0.00	$-3.58M	-